Is a stable or decreasing prolactin level in a patient with prolactinoma a surrogate marker for lack of tumor growth?

Pituitary

Volumn 17, Issue 2, 2014, Pages 97-102

  Alkabbani, Abdulrahman G ^a   Mon, Sann Y ^a   Hatipoglu, Betul ^a   Kennedy, Laurence ^a   Faiman, Charles ^a   Weil, Robert J ^a   Hamrahian, Amir H ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

MRI; Prolactin; Prolactinoma; Tumor size

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; PERGOLIDE; PROLACTIN;

ADULT; AGED; ARTICLE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME;

ADULT; AGED; CELL PROLIFERATION; DISEASE PROGRESSION; DOPAMINE AGONISTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROLACTIN; PROLACTINOMA; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84898800099     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-013-0473-5     Document Type: Article

References (23)

1. Kars M, Dekkers OM, Pereira AM, Romijn JA (2010) Update in prolactinomas. Neth J Med 68:104-112
2. Mancini T, Casanueva FF, Giustina A (2008) Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am 37:67-99 (viii)
3. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA, Endocrine Society (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:273-288
4. Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G (1997) Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82:3574-3579
5. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A (2006) Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65:265-273
6. Klibanski A (2010) Clinical practice. Prolactinomas. N Engl J Med 362:1219-1226
7. Biller BM, Luciano A, Crosignani PG, Molitch M, Olive D, Rebar R, Sanfilippo J, Webster J, Zacur H (1999) Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med 44:1075-1084
8. Schlechte JA (2007) Long-term management of prolactinomas. J Clin Endocrinol Metab 92:2861-2865
9. Schlechte JA (2003) Clinical practice. Prolactinoma. N Engl J Med 349:2035-2041
10. Randall BR, Kraus KL, Simard MF, Couldwell WT (2010) Cost of evaluation of patients with pituitary incidentaloma. Pituitary 13:383-384
11. Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A (1989) The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68:412-418
12. March CM, Kletzky OA, Davajan V, Teal J, Weiss M, Apuzzo ML, Marrs RP, Mishell DR Jr (1981) Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas. Am J Obstet Gynecol 139:835-844
13. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline comparative study group. N Engl J Med 331:904-909
14. Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G (2000) Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85:2247-2252
15. Molitch ME (2005) Pharmacologic resistance in prolactinoma patients. Pituitary 8:43-52
16. Breidahl HD, Topliss DJ, Pike JW (1983) Failure of bromocriptine to maintain reduction in size of a macroprolactinoma. Br Med J (Clin Res Ed) 287:451-452
17. Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A, Jaquet P (1996) Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. Eur J Endocrinol 135:413-420
18. Delgrange E, Crabbe J, Donckier J (1998) Late development of resistance to bromocriptine in a patient with macroprolactinoma. Horm Res 49:250-253
19. Scotti G, Scialfa G, Pieralli S, Chiodini PG, Spelta B, Dallabonzana D (1982) Macroprolactinomas: CT evaluation of reduction of tumor size after medical treatment. Neuroradiology 23:123-126
20. Dallabonzana D, Spelta B, Oppizzi G, Tonon C, Luccarelli G, Chiodini PG, Liuzzi A (1983) Reenlargement of macroprolactinomas during bromocriptine treatment: report of two cases. J Endocrinol Invest 6:47-50
21. Lundin P, Bergstrom K, Nyman R, Lundberg PO, Muhr C (1992) Macroprolactinomas: serial MR imaging in long-term bromocriptine therapy. AJNR Am J Neuroradiol 13:1279-1291
22. Kupersmith MJ, Kleinberg D, Warren FA, Budzilovitch G, Cooper P (1989) Growth of prolactinoma despite lowering of serum prolactin by bromocriptine. Neurosurgery 24:417-423
23. Saeki N, Nakamura M, Sunami K, Yamaura A (1998) Surgical indication after bromocriptine therapy on giant prolactinomas: effects and limitations of the medical treatment. Endocr J 45:529-537